Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levcromakalim-Induced Cerebral Changes in Migraine
NCT05565001Unknown
- Sponsor
- Dansk Hovedpinecenter
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial comparing Levcromakalim with Placebo (2 arms). Primary endpoint: Dynamic diffusion weighted image at 160 months. Status: unknown.
02
Drugs
levcromakalim
Beyond the preview
Go deeper on NCT05565001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05565001.